Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies

Vaccine

Volumn 34, Issue 50, 2016, Pages 6417-6425

  Coudeville, Laurent ^a   Baurin, Nicolas ^a   Vergu, Elisabeta ^b  

^a SANOFI PASTEUR   (France)

^b INRA Institut National de la Recherche Agronomique   (France)

Author keywords

Dengue; Flavivirus; Modeling; Tetravalent dengue vaccine

Indexed keywords

DENGUE VACCINE;

ARTICLE; BASIC REPRODUCTION NUMBER; DENGUE; DRUG EFFICACY; EFFICACY PARAMETERS; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MODEL; MONTE CARLO METHOD; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEROTYPE; VIRUS TRANSMISSION; ASIA; DISEASE TRANSMISSION; IMMUNOLOGY; PREVENTION AND CONTROL; SOUTH AND CENTRAL AMERICA; STATISTICAL MODEL; TRANSMISSION; TREATMENT OUTCOME;

ASIA; BASIC REPRODUCTION NUMBER; CLINICAL TRIALS, PHASE III AS TOPIC; DENGUE; DENGUE VACCINES; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; LATIN AMERICA; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 84960334283     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.023     Document Type: Article

References (40)

1. [1] World Health O, Dengue and dengue haemorrhagic fever, fact sheet No. 117. 2015 〈http://www.whoint/mediacentre/factsheets/fs117/en/〉.
2. [2] Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
3. [3] Murray, N.E., Quam, M.B., Wilder-Smith, A., Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5 (2013), 299–309.
4. [4] OhAinle, M., Balmaseda, A., Macalalad, A.R., Tellez, Y., Zody, M.C., Saborio, S., et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med, 3, 2011, 114ra28.
5. [5] Simmons, M., Teneza-Mora, N., Putnak, R., Advances in the development of vaccines for dengue fever. Vaccine: Dev Ther 2 (2012), 1–14.
6. [6] Tran, N.H., Luong, C.Q., Vu, T.Q.H., Lang, J., Vu, Q.D., Bouckenooghe, A., et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin, 3, 2012, 1000162.
7. [7] Leo, Y.S., Wilder-Smith, A., Archuleta, S., Shek, L.P., Chong, C.Y., Leong, H.N., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: Phase II randomized controlled trial in Singapore. Hum Vaccines Immunother 8 (2012), 1259–1271.
8. [8] Lanata, C.F., Andrade, T., Gil, A.I., Terrones, C., Valladolid, O., Zambrano, B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 30 (2012), 5935–5941.
9. [9] Morrison, D., Legg, T.J., Billings, C.W., Forrat, R., Yoksan, S., Lang, J., A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201 (2010), 370–377.
10. [10] Poo, J. GF, Forrat, R., Zambrano, B., Lang, J., Dayan, G.H., Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 30 (2011), e9–e17.
11. [11] Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380 (2012), 1559–1567.
12. [12] Capeding, R.Z., Luna, I.A., Bomasang, E., Lupisan, S., Lang, J., Forrat, R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29 (2011), 3863–3872.
13. [13] Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2015), 113–123.
14. [14] Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
15. [15] Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2015), 113–123.
16. [16] Group W-VDVM, Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl Trop Dis, 6, 2012, e1450.
17. [17] Coudeville, L., Garnett, G.P., Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS ONE, 7, 2012, e51244.
18. [18] Coudeville L, Baurin N, L'azou M, Guy B. Potential impact of dengue vaccination: insights from two large-scale phase III trials with the tetravalent dengue vaccine. Vaccine. Submittted.
19. [19] Rodriguez-Barraquer, I., Mier-y-Teran-Romero, L., Burke, D.S., Cummings, D.A., Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis, 7, 2013, e2126.
20. [20] Halloran, M.E., Haber, M., Longini, I.M. Jr., Struchiner, C.J., Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 133 (1991), 323–331.
21. [21] Toni, T., Welch, D., Strelkowa, N., Ipsen, A., Stumpf, M.P., Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. J. R. Soc. Interface 6 (2009), 187–202 (the Royal Society).
22. [22] Sisson, S.A., Fan, Y., Tanaka, M.M., Sequential Monte Carlo without likelihoods. Proc Natl Acad Sci USA 104 (2007), 1760–1765.
23. [23] Spiegelhalter, D.J., Best, N.G., Carlin, B.P., Van Der Linde, A., Bayesian measures of model complexity and fit. J R Stat Soc: Ser B (Stat Methodol) 64 (2002), 583–639.
24. [24] Ferguson, N.M., Donnelly, C.A., Anderson, R.M., Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys. Philos Trans R Soc London, Ser B: Biol Sci 354 (1999), 757–768.
25. [25] Imai, N., Dorigatti, I., Cauchemez, S., Ferguson, N.M., Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries. PLoS Negl Trop Dis, 9, 2015, e0003719.
26. [26] Shepard, D.S., Undurraga, E.A., Betancourt-Cravioto, M., Guzmán, M.G., Halstead, S.B., Harris, E., et al. Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis, 8, 2014, e3306.
27. [27] Rodriguez-Barraquer, I., Buathong, R., Iamsirithaworn, S., Nisalak, A., Lessler, J., Jarman, R.G., et al. Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control. Am J Epidemiol 179 (2014), 353–360.
28. [28] Mizumoto, K., Ejima, K., Yamamoto, T., Nishiura, H., On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis 51 (2014), 153–164.
29. [29] Reich, N.G., Shrestha, S., King, A.A., Rohani, P., Lessler, J., Kalayanarooj, S., et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface, 10, 2013, 20130414.
30. [30] Anderson, K.B., Gibbons, R.V., Cummings, D.A., Nisalak, A., Green, S., Libraty, D.H., et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209 (2014), 360–368.
31. [31] Sabin, A.B., Research on dengue during World War II. Am J Trop Med Hyg 1 (1952), 30–50.
32. [32] Thai, K.T., Nishiura, H., Hoang, P.L., Tran, N.T.T., Phan, G.T., Le, H.Q., et al. Age-specificity of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis, 5, 2011, e1180.
33. [33] Egger, J.R., Coleman, P.G., Age and clinical dengue illness. Emergy Infect Dis 13 (2007), 924–925.
34. [34] Rodriguez-Barraquer, I., Mier-y-Teran-Romero, L., Schwartz, I.B., Burke, D.S., Cummings, D.A., Potential opportunities and perils of imperfect dengue vaccines. Vaccine 32 (2014), 514–520.
35. [35] Grange, L., Simon-Loriere, E., Sakuntabhai, A., Gresh, L., Paul, R., Harris, E., Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol, 5, 2014, 280.
36. [36] Fine, P., Eames, K., Heymann, D.L., “Herd immunity”: a rough guide. Clin Infect Dis 52 (2011), 911–916.
37. [37] De Angelis, D., Presanis, A.M., Birrell, P.J., Tomba, G.S., House, T., Key challenges in infectious disease modelling using data from multiple sources. Epidemics, 10, 2015.
38. [38] Andrieu, C., Doucet, A., Holenstein, R., Particle markov chain monte carlo methods. J R Stat Soc: Ser B: Stat Methodol 72 (2010), 269–342.
39. [39] Brooks-Pollock, E., Roberts, G.O., Keeling, M.J., A dynamic model of bovine tuberculosis spread and control in Great Britain. Nature 511 (2014), 228–231.
40. [40] Hadinegoro, S.R., Arredondo-Garcia, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med, 2015.